There are 2789 resources available
1150TiP - A phase II, open-label, multi-dose study of [89Zr]Zr-Df-IAB22M2C (CD8 cell PET tracer) PET/CT in patients with selected advanced or metastatic solid malignancies scheduled to receive standard of care immunotherapy, as single agent or in combination
Presenter: Kim Margolin
Session: ePoster Display
1152P - Real-world outcomes in resected stage IB-IIIA EGFR mutated NSCLC in Canada: Analysis from the POTENT study
Presenter: M. Kuruvilla
Session: ePoster Display
1307P - Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1–positive (TPS ≥50%), advanced NSCLC in Japan
Presenter: Yasushi Goto
Session: ePoster Display
1308P - Efficacy and safety of anti-PD-1 therapy plus anlotinib in previously treated advanced NSCLC
Presenter: Xin Lv
Session: ePoster Display
1309P - A multicenter phase I study of radium-223 (Ra-223) plus pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC)
Presenter: Martin Reck
Session: ePoster Display
1310P - Toripalimab combined with chemotherapy as second-line treatment of advanced non-small cell lung cancer (NSCLC): A single center retrospective study
Presenter: man Jiang
Session: ePoster Display
1311P - The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy
Presenter: Emma Zattarin
Session: ePoster Display
1312P - Prognostic impact of KRAS status in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor monotherapy
Presenter: Giacomo Pelizzari
Session: ePoster Display
1140P - Validation of a deep learning model for the classification of lung cancer in a large cohort of biopsied samples
Presenter: Gouji Toyokawa
Session: ePoster Display
1141P - Prediction of cancer genomic instability using MALDI-imaging
Presenter: Wanja Kassuhn
Session: ePoster Display